Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase NA 1Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 11Neoplasm Metastasis 8Prostatic Neoplasms 6Triple Negative Breast Neoplasms 5Multiple Myeloma 5Lymphoma, Mantle-Cell 5Lymphoma 5Lung Neoplasms 5Leukemia, Myeloid, Acute 4Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Biphenotypic, Acute 3Hematologic Neoplasms 3Fallopian Tube Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Liposarcoma 2Glioma 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2

Interventions

fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 4Rituximab 3Immunoglobulin G 3Everolimus 3Disulfides 3Cyclosporine 3pembrolizumab 2mogamulizumab 2fludarabine 2Whole-Body Irradiation 2Tacrolimus 2ProMune 2Photopheresis 2Mycophenolic Acid 2Methotrexate 2Lenalidomide 2Gene Expression Profiling 2Etoposide 2Cyclophosphamide 2Busulfan 2Bortezomib 2veliparib 1romidepsin 1navitoclax 1magrolimab 1liposomal doxorubicin 1indolepropanol phosphate 1flt3 ligand protein 1ethanolamine oleate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Mycosis Fungoides × Biopsy × Clear all
NCT04541017 2025-10-16

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

National Cancer Institute (NCI)

Phase 1/2 Terminated
8 enrolled 8 charts
Lymphoid

Mycosis Fungoides, Sezary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡